PMHS · XBRL financial data
Polomar Health Services financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PMHS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Revenue | 42 | 59 | 648 |
| Cost of revenue | 4 | 28 | 188 |
| Gross profit | 38 | 31 | 460 |
| General and administrative | 270 | 1,284 | 10,944 |
| Total operating expenses | 270 | 1,330 | 11,010 |
| Operating income (loss) | (270) | (1,299) | (10,550) |
| Interest expense | 0 | 42 | 151 |
| Net income (loss) | (417) | (1,341) | (10,701) |
| Earnings per share, basic USD per share | (0.02) | (0.05) | (0.39) |
| Earnings per share, diluted USD per share | (0.02) | (0.05) | (0.39) |
| Weighted average shares, basic thousands of shares | 17,430 | 27,656 | 27,764 |
| Weighted average shares, diluted thousands of shares | 26,123 | 27,656 | 27,764 |
- † Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (PMHS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 0 | 6 | 132 |
| Inventory | 3 | 69 | 94 |
| Total current assets | 0 | 77 | 323 |
| Property and equipment, net | — | 81 | 43 |
| Right-of-use asset | 82 | 49 | 15 |
| Total assets | 0 | 9,952 | 390 |
| Total current liabilities | 14 | 1,338 | 1,612 |
| Lease liability, non-current | 49 | 15 | — |
| Total liabilities | 14 | 1,353 | 1,612 |
| Accumulated deficit | (1,398) | (2,911) | (13,612) |
| Total stockholders' equity | (14) | 8,599 | (1,222) |
| Total liabilities and equity | 0 | 9,952 | 390 |
| Common shares outstanding (cover page) thousands of shares | 109,138 | 26,658 | 28,053 |
- † Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (PMHS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (417) | (1,341) | (10,701) |
| Stock-based compensation | — | — | 130 |
| Net cash from operating activities | (372) | (1,020) | (396) |
| Purchases of property and equipment | — | 91 | — |
| Net cash from investing activities | — | (91) | — |
| Proceeds from issuing common stock | 216 | — | — |
| Net cash from financing activities | 146 | 1,108 | 522 |
| Net change in cash | (225) | (3) | 126 |
- † Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.